Source: Virtual Congress 2021 – Medical education in respiratory medicine



Rating:

Share or cite this content

Citations should be made in the following way:
R. Bontsevich (Belgorod, Russian Federation), K. Shchurovskaya (Belgorod, Russian Federation), G. Batisheva (Voronezh, Russian Federation), N. Goncharova (Voronezh, Russian Federation), A. Adonina (Belgorod, Russian Federation), A. Gavrilova (Belgorod, Russian Federation), T. Pokrovskaia (Belgorod, Russian Federation). Assessment of medical undergraduates’ relation to pneumococcal conjugate vaccine use. 535

Member's Comments

No comment yet.

Related content which might interest you: Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands Source: Eur Respir J 2015; 46: 1407-1416 Year: 2015 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Use of the pneumococcal 23-valent polysaccharide vaccine in recruits in Russia Source: Eur Respir J 2004; 24: Suppl. 48, 363s Year: 2004 Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population Source: Eur Respir J 2016; 48: 1492-1496 Year: 2016 Attitudes of medical students towards the influenza vaccination Source: International Congress 2017 – Medical education, web and internet Year: 2017 Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Beliefs and attitudes of health care workers on influenza and pneumococcal vaccine Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care Year: 2012 Pneumococcal vaccine: clinical factors as facilitators or barriers to vaccination Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 673s Year: 2005 Additive preventive effect of influenza and pneumococcal vaccines in elderly persons Source: Eur Respir J 2004; 23: 363-368 Year: 2004 Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Source: Eur Respir J 2010; 36: 608-614 Year: 2010 Pneumococcal vaccination: current and future issues Source: Eur Respir J 2001; 18: 184-195 Year: 2001 Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV) Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013) Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012